ArticleJournal of the Turkish German Gynecological Association2026
A bioinformatics approach to identify potential biomarkers of high-grade ovarian cancer.
Article in Journal of the Turkish German Gynecological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ovarian cancer proteomic landscape changes across different pathological stages and biomarker-sets identified with integrative multiomics analysis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: High-grade ovarian cancer (HGOC) remains a significant therapeutic challenge due to its aggressive nature and poor prognosis. The aim was to elucidate the molecular drivers of HGOC through an integrated bioinformatics analysis. Material and Methods: The microarray datasets (GSE6008 and GSE14764) served as the training set, while an independent microarray dataset (GSE23603) was used as the validation set. These datasets included low- and high-grade ovarian tumor samples and were downloaded from the ArrayExpress database. Selection criteria included clearly classified low-grade ovarian cancer and HGOC samples, as well as platform and sample processing methods compatibility. After normalization, differentially expressed genes (DEGs) were obtained using R software. Functional enrichment analysis [including gene ontology (GO) and pathway analysis] was performed using the DAVID database. A protein-protein interaction (PPI) network was constructed by STRING to identify hub genes associated with HGOC. Results: A total of 106 common DEGs were identified across all three datasets, including 66 up-regulated and 40 down-regulated genes. Given the study's focus on potential oncogenic drivers, subsequent analyses prioritized the 66 up-regulated genes. The DEGs were classified into three groups by GO terms (21 biological process, 10 molecular function and 12 cellular component). Kyoto Encyclopedia of Genes and Genomes pathway analysis showed enrichment in metabolic pathways, oxidative phosphorylation, drug metabolism, and cell cycle regulation. The top nine up-regulated hub genes in the PPI network were Conclusion: The identification of these hub genes and pathways may represent an important step forward in our understanding of HGOC. While down-regulated genes may also hold biological significance, their analysis was beyond the scope of this study and warrants future investigation. Further experimental validation is needed to confirm the roles of the identified genes in disease pathogenesis and their potential as biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.